Korea to Cut New Drug Review Time Below US, Europe Levels Starting June

MFDS Review System Innovation Plan 195 Additional Staff to Strengthen Sector-Specific Verification Review Period Shortened from 420 Days to 240 Days

Culture|
|
By Park Ji-soo
|

Content not available. Please visit the original article.

#MFDS#DrugApproval#KoreaPharma#Biosimilar#DrugRegulation#ParallelReview#Pharmaceuticals

Original reporting by Park Ji-soo for Seoul Economic Daily.

AI-translated from Korean. Quotes from foreign sources are based on Korean-language reports and may not reflect exact original wording.

View Korean originalTranslation Policy
AI PRISM cover art

🎧Listen to AI PRISM·AI PRISM

KOSPI Stages 370-Point Intraday Reversal as ETF Rebalancing Reshapes Semiconductor Flows | June 12 2026

00:0004:17
← Back to Home

AI KEY

Preview
Korean Corporate Intelligence HubKOSPI · KOSDAQ · 12 sectors

A live, cap-weighted view of every KOSPI and KOSDAQ sector, with same-day Korean reporting distilled by company — built for foreign investors, correspondents and analysts who need to scan Korea before the next session.

Open in full screen

Korea Chaebol Tree

Preview
Families Behind the GroupsKFTC May 2026 · DART filings

An English-first interactive map of Samsung, SK, Hyundai, LG and Lotte — built for foreign investors, correspondents and analysts. Korea translates companies into English. We translate the families behind them.

Open in full screen

SIGNAL

Pre-register
English Edition · Capital MarketsM&A · IPO · PE · Fund Flows

Pre-register for SIGNAL English Edition — a premium subscription bringing Korean capital markets coverage (M&A, IPOs, private equity, fund flows) to global institutional investors. First access to the 50% introductory rate.

Open in full screen